Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 8;374(1773):20180294. doi: 10.1098/rstb.2018.0294

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s)

Published by the Royal Society. All rights reserved.

PMC Copyright notice

Figure 3. — Therapeutic vaccination with HLA-A2.1 restricted epitope DNA vaccines targeting early gene E1. Control (HLA-A2.1-negative) and HLA-A2.1 transgenic rabbits (HLA-A2.1-positive) rabbits are both positive for rabbit MHCI as shown by immunohistochemistry on the left. Animals infected with SfPV1 were divided into four groups and vaccinated with two different E1 epitope DNA vaccines (E1/303–311 and E1/161–169) at week 4 post-infection [95]. Two booster immunizations were conducted at three-week intervals (arrows). Significantly smaller tumours were found in the transgenic rabbit group immunized with epitope E1/303–311 when compared with the other three groups (by geometric mean diameter (GMD) in mm, p < 0.05, unpaired Student t-test) indicating the immune response was effective and specific.